profile

biopharmadealmakers.nature.com | September 2019 | B17 ADVERTISER RETAINS SOLE RESPONSIBILITY FOR CONTENT

ADVERTISEMENT FEATURE

Wallonia: a world of life sciences opportunities in the heart of EuropeOver the past two decades, Wallonia has emerged as a global powerhouse in different strategic areas in the health sector.

Situated in the heart of Europe, the Belgian region of Wallonia has created a vibrant innovation ecosystem by equally investing in, and supporting the growth of, scientific excellence and entrepreneurial leadership. The life science sector in particular has experienced remarkable growth and dynamism, and is gaining increased international recognition (Fig. 1).

Key drivers behind this dynamic innovation ecosys-tem are Wallonia Export-Investment Agency (Awex), and BioWin, the health competitiveness cluster of the Walloon region.

Awex: investing in a unique innovation ecosystemWallonia Export-Investment Agency (Awex) is a public interest organization in charge of promoting foreign trade and attracting foreign investments to Wallonia with the support of the regional govern-ment. As such, Awex helps drive regional innovation in areas ranging from aeronautics and space or envi-ronmental technologies to transport and logistics or life sciences. Awex serves as a one-stop destina-tion both for Walloon exporting companies and for potential foreign investors interested in partaking in Wallonia’s unique innovation ecosystem.

Wallonia, with its world-class research institutions, a highly trained workforce, and one of the densest transportation networks in Europe, provides an excel-lent gateway to and out of the European market. Awex embodies the region’s philosophy of dynamic and open innovation through technological partner-ships and a robust ecosystem.

BioWin: accelerating life sciences innovationBioWin is the life sciences gateway for Wallonia. The cluster’s mission is to help drive innovation and to develop a competitive knowledge base and job opportunities in the health sector. BioWin takes a collaborative approach that brings together all players involved in this space: academic and clinical research laboratories, research centers, large indus-trial groups, small and medium-sized enterprises, service providers, engineering colleges and univer-sities, business incubators, investors, policy makers, and associated bodies.

BioWin has six domains of strategic importance: biopharma, cell therapy, medical devices and diag-nostic in vitro, radiation applied to health, biomanu-facturing, and data science. Its focus on regenerative medicine and cell therapies serves as an example of how a concerted effort to (1) support research and development projects and build a network

of infrastructures and platforms, (2) support busi-ness growth, (3) develop high-level skilled training programs, and (4) generate international business development opportunities can, over a short period of time, result in a thriving industry that is rapidly becoming a global reference in this space.

Marc DechampsDirector of International AffairsBioWin asblGosselies, BelgiumTel: +32 496 59 03 54Email: marc.dechamps@biowin.org

Alphi Cartuyvels, Deputy General ManagerEurope & North AmericaWallonia Export-Investment AgencyBrussels, BelgiumTel: +32 81 33 28 64Email: acartuyvels@investinwallonia.be

contac

t

Fig. 1 | The many strengths of Wallonia. CDMO, contract development and manufacturing organization; GMP, good manufacturing practice; R&D, research and development.

BioWin asblwww.biowin.org

Wallonia Export-Investment Agencywww.investinwallonia.be

“Key drivers behind this

dynamic innovation ecosystem are Awex, and BioWin, the health competitiveness cluster of the Walloon region